[Clinical study of albendazole therapy for strongyloidiasis].
We reported the efficacy of albendazole (ABZ) for the treatment of 27 patients with strongyloidiasis. Twenty-seven patients, 23 males and 4 females, received 200 mg of ABZ one hour before breakfast and supper for 3 days and this treatment was repeated 2 weeks later. The following results were obtained: 1) The eradication rate at 2 weeks after the initial treatment was 70.4% (19 of 27 patients) and 2 weeks after the second course was 66.7% (16 of 24 patients). 2) One patients (3.7%) complained of abdominal pain after the first treatment. Four patients (14.8%) complained of headache (n = 2), nausea (n = 1) and exanthema (n = 1) after the second treatment. But all symptoms were mild and required no treatment and subsided in a few days. 3) Positive rate of HTLV-1 antibody was 45.8% in the patients. As described above, side effects occurred in some cases, although they were mild and transient. From these results, it can be concluded that on increased dose of ABZ could be much more favorable for the treatment of strongyloidiasis.
Niimura
S
S
First Department of Internal Medicine, Faculty of Medicine, University of the Ryukyus.
Hirata
T
T
Zaha
O
O
Nakamura
H
H
Kouchi
A
A
Uehara
T
T
Uechi
H
H
Ohshiro
J
J
Shikiya
K
K
Kinjo
F
F
D000328:Adult; D000368:Aged; D015766:Albendazole / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D015481:HTLV-I Antibodies / Q000032:analysis; D006801:Humans; D008297:Male; D008875:Middle Aged; D013322:Strongyloidiasis / Q000188:drug therapy*
D015481:HTLV-I Antibodies; D015766:Albendazole